PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12202950-5 2002 Quantitative affinity purification of detergent-insoluble complexes using biotinylated folate or specific antibodies demonstrated a strong association of the homologous FR-alpha and FR-beta in the same detergent-insoluble complex and separate complexes containing either PLAP or caveolin. Folic Acid 87-93 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 169-177 9426700-5 1998 FR-alpha mRNA expression in the cell lines was in good agreement with the corresponding protein expression evaluated by cellular folic acid binding and immunofluorescence analysis, using a specific monoclonal antibody (MAb) (MOv18). Folic Acid 129-139 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 0-8 12095688-1 2002 The KB cell, a transformed human cell line, constitutively expresses a high level of the glycosylphosphatidylinositol (GPI) anchored folate receptor protein alpha (FR alpha) and thereby can grow in medium containing <1 nM folate. Folic Acid 133-139 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 164-172 12095688-2 2002 When transferred from a folate-replete (FR) medium to one folate-deficient (FD), intracellular folate diminishes about 50-fold and expression of the FR alpha increases 6-fold. Folic Acid 24-30 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 149-157 12095688-2 2002 When transferred from a folate-replete (FR) medium to one folate-deficient (FD), intracellular folate diminishes about 50-fold and expression of the FR alpha increases 6-fold. Folic Acid 58-64 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 149-157 12095688-2 2002 When transferred from a folate-replete (FR) medium to one folate-deficient (FD), intracellular folate diminishes about 50-fold and expression of the FR alpha increases 6-fold. Folic Acid 58-64 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 149-157 9545095-5 1998 The folate receptor alpha (FR-alpha) gene codes for the protein responsible for binding folate, which is the first, and only, folate-dependent step in folate transport. Folic Acid 4-10 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 27-35 9545095-5 1998 The folate receptor alpha (FR-alpha) gene codes for the protein responsible for binding folate, which is the first, and only, folate-dependent step in folate transport. Folic Acid 88-94 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 27-35 9545095-5 1998 The folate receptor alpha (FR-alpha) gene codes for the protein responsible for binding folate, which is the first, and only, folate-dependent step in folate transport. Folic Acid 88-94 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 27-35 9426700-10 1998 Treatment with the N-hydroxysuccinimide of folic acid, which blocks FR-alpha activity, showed only a partial inhibition (about 20%) of folate internalization in all the cell lines. Folic Acid 43-53 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 68-76 9166787-5 1997 Substitution of the amino-terminal portion (residues 1-92) in the mature FR-alpha polypeptide with the corresponding segment of FR-beta resulted in folate binding characteristics similar to FR-beta. Folic Acid 148-154 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 73-81 9166787-7 1997 In this fashion, it was determined that the alanine residue at position 49 in FR-alpha was critical for its functional divergence from FR-beta, since substitution at this position with Leu (the corresponding residue in FR-beta) resulted in the folate binding characteristics of FR-beta. Folic Acid 244-250 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 78-86 9166787-8 1997 Reciprocal substitution in FR-beta with peptide 1-92 of FR-alpha resulted in poor expression of a [3H]folic acid binding protein. Folic Acid 102-112 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 56-64 9166787-9 1997 By analysis of chimeric constructs, the poor [3H]folic acid binding of the FR-alpha(1-92)/beta(93-237) chimera could be attributed to interference of a short segment from FR-alpha in the vicinity of Ala 49 (peptide 39-59) with proper folding of the chimera. Folic Acid 49-59 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 75-83 7513252-10 1994 KB cells and JEG-3 cells grown at low folate concentrations further up-regulated FR-alpha but not FR-beta. Folic Acid 38-44 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 81-89 8061055-1 1994 The folate receptor (FR), an essential component in the process of folate uptake in various cells, is known to exist in three isoforms, FR-alpha, FR-beta and FR-gamma, with differential tissue expression. Folic Acid 4-10 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 136-144 7513252-11 1994 CONCLUSIONS: Although FR-beta is the more common isoform, FR-alpha and FR-beta are differentially regulated in normal tissues, carcinomas, nonepithelial malignancies, and immortalized cells or in response to changes in extracellular folate concentrations. Folic Acid 233-239 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 58-66 35185910-3 2022 Over the past decade, selective expression of folate receptor beta (FRbeta), a glycosylphosphatidylinositol-anchored plasma membrane protein, on myeloid cells has emerged as an attractive target for macrophage imaging by exploiting the high binding affinity of folate-based PET tracers. Folic Acid 261-267 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 68-74 32618744-4 2021 In the last few years HER2/neu, folic acid-alpha (FRalpha) and Trop-2 overexpression have been exploited as excellent targets by novel ADCs such as Trastuzumab emtansine (T-DM1), SYD985, IMGN853 (Mirvetuximab soravtansine) and Sacituzumab govitecan (SG, IMMU-132) in multiple tumors including ovarian, endometrial and cervical cancers. Folic Acid 32-42 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 50-57 33670773-0 2021 Heterocyclic Substitutions Greatly Improve Affinity and Stability of Folic Acid towards FRalpha. Folic Acid 69-79 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 88-95 33670773-3 2021 The folic acid (FA) binding affinity to the FRalpha active site provides a basis for designing more specific targets for FRalpha. Folic Acid 4-14 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 44-51 33670773-3 2021 The folic acid (FA) binding affinity to the FRalpha active site provides a basis for designing more specific targets for FRalpha. Folic Acid 4-14 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 121-128 33321157-6 2021 Folate-mediated targeting of FRbeta in M2 TAMs and NSCLC cells effectively inhibited tumor growth and the stimulus-responsive drug release reduced the toxic side effects of the drug. Folic Acid 0-6 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 29-35 33203700-4 2021 This FRbeta+ subpopulation could be selectively targeted with folate-linked drugs. Folic Acid 62-68 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 5-11 32919191-6 2020 Folate receptor-beta (FR-beta) is a cell surface glycosylphosphatidylinositol-anchored glycoprotein that can mediate the unidirectional transport of folate into cells. Folic Acid 149-155 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 22-29 32659629-6 2020 The data show that introducing long functional groups in folate will increase the binding affinity with FRalpha but will decrease the binding affinity with FRbeta. Folic Acid 57-63 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 104-111 32659629-6 2020 The data show that introducing long functional groups in folate will increase the binding affinity with FRalpha but will decrease the binding affinity with FRbeta. Folic Acid 57-63 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 156-162 29616859-3 2018 FR-alpha and FR-beta are present on many cancers with little expression in normal tissues; leading to the testing of at least six folate-targeted drugs in human clinical trials for various cancers. Folic Acid 130-136 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 0-8 31926453-2 2020 Placental transfer of folate is mediated by folate receptor alpha (FR-alpha), proton coupled folate transporter (PCFT), and reduced folate carrier (RFC). Folic Acid 22-28 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 67-75 31926453-2 2020 Placental transfer of folate is mediated by folate receptor alpha (FR-alpha), proton coupled folate transporter (PCFT), and reduced folate carrier (RFC). Folic Acid 44-50 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 67-75 32545327-1 2020 The folate receptor (FR) is a promising cell membrane-associated target for molecular imaging and radionuclide therapy of cancer (FR-alpha) and potentially also inflammatory diseases (FR-beta) through use of folic acid-based radioconjugate. Folic Acid 208-218 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 130-138 32545327-1 2020 The folate receptor (FR) is a promising cell membrane-associated target for molecular imaging and radionuclide therapy of cancer (FR-alpha) and potentially also inflammatory diseases (FR-beta) through use of folic acid-based radioconjugate. Folic Acid 208-218 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 184-191 29486262-1 2018 In our previous study, we demonstrated that folate-appended methyl-beta-cyclodextrin (FA-M-beta-CyD) was a promising antitumor agent for the treatment of folate receptor-alpha (FR-alpha)-expressing tumors. Folic Acid 44-50 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 177-185 29737910-7 2018 Therefore, folate (FA) is being evaluated as an active targeting moiety for FR-alpha+ ovarian cancer. Folic Acid 11-17 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 76-84 26090596-1 2015 Folate receptors alpha (FRalpha) and beta (FRbeta) are two isoforms of the cell surface glycoprotein that binds folate. Folic Acid 112-118 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 24-31 29435118-8 2018 Thus, while folate-targeted imaging of lung cancer patients might accurately reflect the expression of FR-alpha on lung cancer cells, imaging of pancreatic cancer patients could mislead a physician into treating a nonresponding patient. Folic Acid 12-18 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 103-111 29435118-9 2018 Overall, these data suggest that an independent analysis of both FR-alpha and FR-beta should be obtained to predict the potential efficacy of a folate-targeted drug. Folic Acid 144-150 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 65-73 27221054-6 2016 FRalpha antibodies prevented the uptake and also the corresponding conjugate without folate was not taken up. Folic Acid 85-91 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 0-7 27221054-8 2016 An excess of free folate as competitor for the FRalpha-mediated uptake completely inhibited the photocytotoxicity. Folic Acid 18-24 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 47-54 28110184-1 2017 Dendrimers functionalized with folic acid (FA) are drug delivery systems that can selectively target cancer cells with folate receptors (FR-alpha) overexpression. Folic Acid 31-41 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 137-145 21542552-6 2004 The FR-alpha isoform is expressed on the apical (luminal) surface of epithelial cells in limited tissues, and because of no vascular supply, it is inaccessible to exogenous folate conjugates with the exception of the FR-alpha isoforms on the proximal tubules of kidneys (1-3). Folic Acid 173-179 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 4-12 24446917-4 2014 The present study quantitates the number of cell surface FR-alpha and FR-beta following exposure to saturating concentrations of a variety of folate-linked molecules and anti-FR antibodies, including the unmodified vitamin, folate-linked drug mimetics, multifolate derivatized nanoparticles, and monoclonal antibodies to FR. Folic Acid 142-148 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 57-65 23851396-2 2013 Although expressed at very low levels in most tissues, folate receptors, especially FRalpha, are expressed at high levels in numerous cancers to meet the folate demand of rapidly dividing cells under low folate conditions. Folic Acid 55-61 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 84-91 23851396-2 2013 Although expressed at very low levels in most tissues, folate receptors, especially FRalpha, are expressed at high levels in numerous cancers to meet the folate demand of rapidly dividing cells under low folate conditions. Folic Acid 154-160 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 84-91 23851396-3 2013 The folate dependency of many tumours has been therapeutically and diagnostically exploited by administration of anti-FRalpha antibodies, high-affinity antifolates, folate-based imaging agents and folate-conjugated drugs and toxins. Folic Acid 4-10 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 118-125 23819524-9 2013 Moreover, both folate-PET imaging agents also bind to FR-alpha which is overexpressed on multiple human cancers. Folic Acid 15-21 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 54-62 21542550-5 2004 Second, FR-alpha isoform is overexpressed on ~40% of human cancers, where it is completely accessible to folate conjugates. Folic Acid 105-111 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 8-16 21542551-5 2004 Second, FR-alpha isoform is overexpressed on ~40% of human cancers, where it is completely accessible to folate conjugates. Folic Acid 105-111 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 8-16 23851396-4 2013 To understand how folate binds its receptors, we determined the crystal structure of human FRalpha in complex with folic acid at 2.8 A resolution. Folic Acid 18-24 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 91-98 23851396-4 2013 To understand how folate binds its receptors, we determined the crystal structure of human FRalpha in complex with folic acid at 2.8 A resolution. Folic Acid 115-125 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 91-98 23851396-5 2013 FRalpha has a globular structure stabilized by eight disulphide bonds and contains a deep open folate-binding pocket comprised of residues that are conserved in all receptor subtypes. Folic Acid 95-101 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 0-7 23880302-5 2013 After the selection of the best model, a folic acid molecule was docked "in silico" onto the putative binding site and its binding mode was compared with that of vintafolide, a much larger molecule designed as a chemotherapy agent targeting specifically FRalpha. Folic Acid 41-51 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 254-261 23880302-6 2013 In both cases, a 40ns molecular dynamics trajectory was calculated, providing suggestions regarding the key structural determinants driving the affinity and specificity of FRalpha for folic acid with respect to other folate homologues. Folic Acid 184-194 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 172-179 23880302-6 2013 In both cases, a 40ns molecular dynamics trajectory was calculated, providing suggestions regarding the key structural determinants driving the affinity and specificity of FRalpha for folic acid with respect to other folate homologues. Folic Acid 217-223 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 172-179 21542552-10 2004 Second, the FR-alpha isoform is overexpressed in ~40% of human cancer tissues, where it is completely accessible to folate conjugates. Folic Acid 116-122 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 12-20 21542552-19 2004 MRI with Gd.DOTA.Folate in tumor-bearing mice showed an increase in R1 with clear enhancement on the MRI images in a human ovarian carcinoma (IGROV-1) xenograft overexpressing the FR-alpha isoform, but no change was observed in a FR-alpha-negative human ovarian carcinoma (OVCAR-3) xenograft. Folic Acid 17-23 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 180-188 21542552-19 2004 MRI with Gd.DOTA.Folate in tumor-bearing mice showed an increase in R1 with clear enhancement on the MRI images in a human ovarian carcinoma (IGROV-1) xenograft overexpressing the FR-alpha isoform, but no change was observed in a FR-alpha-negative human ovarian carcinoma (OVCAR-3) xenograft. Folic Acid 17-23 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 230-238 17979543-1 2007 Folate biochemical pathway components such as FR-alpha are determinants of response to novel antifolate drugs such as pemetrexed. Folic Acid 0-6 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 46-54 18222534-11 2008 New findings from this study show that FRalpha expression is maintained on metastatic foci and recurrent tumors, suggesting that novel folate-targeted therapies may hold promise for the majority of women with either newly diagnosed or recurrent ovarian cancer. Folic Acid 135-141 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 39-46 17473184-8 2007 Among the transfected 143B sublines, only the 143B-FR alpha was able to uptake 5-methyltetrahydrofolate when the extracellular concentration was reduced to 2 nmol/L, which conferred a growth advantage in physiologic folate concentrations compared with vector-only-transfected cells. Folic Acid 97-103 rabaptin, RAB GTPase binding effector protein 2 Homo sapiens 51-59